- Home
- DAWN vs AMRK Comparison
DAWN vs AMRK Comparison
Compare DAWN & AMRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DAWN
- AMRK
- Stock Information
- Founded
- DAWN 2018
- AMRK 1965
- Country
- DAWN United States
- AMRK United States
- Employees
- DAWN N/A
- AMRK N/A
- Industry
- DAWN Biotechnology: Pharmaceutical Preparations
- AMRK Other Specialty Stores
- Sector
- DAWN Health Care
- AMRK Industrials
- Exchange
- DAWN Nasdaq
- AMRK Nasdaq
- Market Cap
- DAWN 624.8M
- AMRK 593.0M
- IPO Year
- DAWN 2021
- AMRK N/A
- Fundamental
- Price
- DAWN $7.19
- AMRK $27.66
- Analyst Decision
- DAWN Strong Buy
- AMRK Buy
- Analyst Count
- DAWN 7
- AMRK 3
- Target Price
- DAWN $27.86
- AMRK $33.00
- AVG Volume (30 Days)
- DAWN 1.1M
- AMRK 269.1K
- Earning Date
- DAWN 10-29-2025
- AMRK 09-09-2025
- Dividend Yield
- DAWN N/A
- AMRK 3.18%
- EPS Growth
- DAWN N/A
- AMRK N/A
- EPS
- DAWN N/A
- AMRK 0.70
- Revenue
- DAWN $187,638,000.00
- AMRK $10,978,614,000.00
- Revenue This Year
- DAWN $12.56
- AMRK $8.64
- Revenue Next Year
- DAWN $48.02
- AMRK $5.69
- P/E Ratio
- DAWN N/A
- AMRK $36.01
- Revenue Growth
- DAWN 2190.50
- AMRK 13.19
- 52 Week Low
- DAWN $5.64
- AMRK $19.39
- 52 Week High
- DAWN $16.76
- AMRK $47.39
- Technical
- Relative Strength Index (RSI)
- DAWN 52.01
- AMRK 76.95
- Support Level
- DAWN $7.18
- AMRK $22.00
- Resistance Level
- DAWN $7.58
- AMRK $24.64
- Average True Range (ATR)
- DAWN 0.27
- AMRK 1.07
- MACD
- DAWN -0.03
- AMRK 0.29
- Stochastic Oscillator
- DAWN 33.92
- AMRK 97.95
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
About AMRK A-Mark Precious Metals Inc.
A-Mark Precious Metals Inc is a precious metal trading company. It is principally engaged in the wholesale of gold, silver, platinum, copper, and palladium bullion and related products in the form of bars, wafers, coins, and grains. The company's operating segment includes Wholesale Sales and Ancillary Services; Secured Lending and Direct-to-Consumer. It generates maximum revenue from the Wholesale Trading and Ancillary Services segment. The Wholesale Trading and Ancillary Services segment comprises business units such as Industrial, Coin and Bar, Trading and Finance, Storage, Logistics, and Mint. Geographically, it derives a majority of its revenue from the United States and the rest from Europe, Asia Pacific, Australia, Africa, and other regions.